About Nanocan Therapeutics
Nanocan Therapeutics is a private company based in National Harbor, Maryland, incorporated in 2020 in Delaware. It has reported $6,184,984 raised in two offerings on Form D since August 2020. Its chief executive is Eric Broyles.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Dec 30, 2022 | Feb 18, 2025 | $5,059,984of $6.4M target | 41 | $123K | Equity, Preferred Stock can convert to underlying shares of Common Stock.Rule 506(b) | Form D ↗ |
| Jul 15, 2020 | Aug 27, 2020 | $1,125,000of $1.4M target | 6 | $187K | EquityRule 506(b) | Form D ↗ |
| Total, two offerings | $6,184,984 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Nanocan Therapeutics's Form D filed Feb 18, 2025.
DK
Dave Krasne
Executive officer
EB
Eric Broyles
Chief Executive Officer and director
JW
Jacques Walker
Executive officer and director